Recon: Purdue’s Sacklers reach terms on $6B opioid settlement with states; Biogen begins layoffs amid sluggish sales of Aduhelm
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy